Youxiang Chen

ORCID: 0000-0003-4218-6133
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Esophageal and GI Pathology
  • Colorectal Cancer Screening and Detection
  • Gastrointestinal disorders and treatments
  • Colorectal Cancer Surgical Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Colorectal Cancer Treatments and Studies
  • Helicobacter pylori-related gastroenterology studies
  • Inflammatory Bowel Disease
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Diverticular Disease and Complications
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Colorectal and Anal Carcinomas
  • Metabolomics and Mass Spectrometry Studies
  • Pancreatitis Pathology and Treatment
  • Gallbladder and Bile Duct Disorders
  • Circular RNAs in diseases
  • Pharmacological Effects of Natural Compounds
  • Esophageal Cancer Research and Treatment
  • Biliary and Gastrointestinal Fistulas
  • Inflammatory Biomarkers in Disease Prognosis
  • Genetic factors in colorectal cancer

First Affiliated Hospital of Nanchang University
2014-2025

Nanchang University
2014-2025

First Affiliated Hospital of Jiangxi Medical College
2023-2025

Jiangxi Chest Hospital
2024

Creative Commons
2019

National Natural Science Foundation of China
2019

China University of Mining and Technology
2016

Edouard Louis Stefan Schreiber Remo Panaccione Peter Bossuyt Luc Biedermann and 95 more Jean–Frédéric Colombel Gareth M. B. Parkes Laurent Peyrin–Biroulet Geert R. D’Haens Tadakazu Hisamatsu Britta Siegmund Kaichun Wu Brigid S. Boland Gil Y. Melmed Alessandro Armuzzi Phillip Levine Jasmina Kalabic Su Chen Ling Cheng Lei Shu W. Rachel Duan Valerie Pivorunas Yuri Sánchez González Ronilda D’Cunha Ezequiel Neimark Kori Wallace Raja Atreya Marc Ferrante Edward V. Loftus Domingo Balderramo Silvina A. Goncalves Juan Lasa Abel Novillo Orlando Ruffinengo Sonja Heeren Walter Reinisch Filip Baert Peter Bossuyt A Colard Olivier Dewit Marc Ferrante Denis Franchimont Edouard Louis Jean‐François Rahier Carlos F. Francesconi Roberto Luiz Kaiser Rogério Serafim Parra Lígia Yukie Sassaki Пламен Пенчев Desislav Stanchev Kenneth Atkinson Melanie Beaton Talat Bessissow Susan Greenbloom Jean-Rene Lachance Allen Lim Remo Panaccione Jean-Michel Samson Scott Shulman Jesse Siffledeen Ignacio Alfaro Carlos Valenzuela Gustavo Walsen Ping An Qian Cao Yan Chen Youxiang Chen Xiang Gao Xiaohua Hou Naizhong Hu Yan Li Fei Liu Mei Liu LU Lungen Zhihua Ran Tongyu Tang Xin Wang Shaoqi Yang Qiang Zhan Guoxin Zhang Hu Zhang Jie Zhang Xiaolan Zhang Jie Zhong Xiaoping Zou Eligio Álvarez Juan Camilo Ricaurte Vladimir Borzan Željko Krznarić Željko Puljiz Martin Bortlík Pavel Svoboda Jan Ulbrych Tomáš Vaňásek Jens Kjeldsen Lars Kristian Munck Anja Poulsen Ezzat Ali Osama Salem Hisham Sawah

Importance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit IL-23) for treatment ulcerative colitis are unknown. Objective To evaluate efficacy and safety when administered as an induction a maintenance therapy patients with colitis. Design, Setting, Participants Two phase 3 randomized trials were conducted. trial was conducted at 261 centers (in 41 countries) enrolled 977 from November 5, 2020, to August 4, 2022 (final follow-up on May 16,...

10.1001/jama.2024.12414 article EN JAMA 2024-07-22

10.1016/s0140-6736(24)01762-8 article EN The Lancet 2024-11-21
David T. Rubin Jessica R. Allegretti Julián Panés Nicole Shipitofsky Shadi Yarandi and 95 more Kuan-Hsiang Gary Huang Matthew Germinaro Rebbecca Wilson Hongyan Zhang Jewel Johanns Brian G. Feagan Tadakazu Hisamatsu Gary R. Lichtenstein Brian Bressler Laurent Peyrin‐Biroulet Bruce E Sands Axel Dignaß О. Аbrahamovych Niazy Abu-farsakh Halyna Afanasieva Hale Akpınar Houssam Al Kharrat Engin Altıntaş Romain Altwegg П. С. Андреев Kazuki Aomatsu Hiroshi Araki Marjorie Argollo Federico Ariel Alessandro Armuzzi Toshifumi Ashida Monika Augustyn Guy Aumais Martín Azum Filip Baert Jozef Baláž Domingo Balderramo Jakob Begun Temenuzhka Berova Lore Billiauws Antonio Blanco Martin Bortlík Fabrizio Bossa Elena Bunkova Mercedes Cabello Qian Cao Flavio Caprioli Rute Cerqueira Karen A. Chachu Patrick Chamouard Chunxiao Chen Yan Chen Baili Chen Dongfeng Chen Hong Chen Youxiang Chen Chou‐Chen Chen Jinwoo Cheon Minhu Chen Cheng-Tang Chiu Chang‐Hwan Choi Elizabeth Chow Michele Cicala A. Cintra Wit Danilkiewicz Olena Datsenko Gert De Hertogh Julio De María L Medina Deliang Liu Pierre Desreumaux Pieter Dewint Shigang Ding Glen Doherty Rossitza Draganova Joris Dutré George Duvall Laurence J. Egan Julien Fahed Lars Fechner Miroslav Fedurco Aykut Ferhat Celik J. C. Fernández Rafał Filip Sigal Fishman Cristina Flores Ronald Fogel Sharyle Fowler Carlos F. Francesconi Toshimitsu Fujii Mikihiro Fujiya Masayuki Fukata Seiichiro Fukuhara Yohei Furumoto G Kiss Waldemar Gachowski Xiang Gao Antonio Gasbarrini Beata Gawdis-Wojnarska Daniel R. Gaya

10.1016/s0140-6736(24)01927-5 article EN The Lancet 2024-12-17

Introduction: Colon cancer is a frequent malignancy, and surgery still the primary therapy for people with colon cancer. Other treatments, including radiation, chemotherapy, biologic therapy, may be utilized as supplement. Chemotherapy, prominent treatment cancer, has failed to provide positive outcomes. This necessitates development of more effective less harmful drugs. Coptisine was discovered inhibit cell line HCT-116 in vivo, decrease growth cells, cause apoptosis vitro (COP) shown...

10.2174/0109298673262553231227075800 article EN Current Medicinal Chemistry 2024-01-12

Backgrounds: Colorectal cancer (CRC) is a highly malignant gastrointestinal malignancy with poor prognosis, which imposes significant burden on patients and healthcare providers globally.Previous studies have established that genes related to glutamine metabolism play crucial role in the development of CRC.However, no yet explored prognostic significance these CRC.Methods: CRC patient data were downloaded from The Cancer Genome Atlas (TCGA), while metabolism-related obtained Molecular...

10.7150/jca.91687 article EN cc-by-nc Journal of Cancer 2024-01-01

ABSTRACT Purpose/Backgrounds Colorectal polyps (CRPs) are precursors to colorectal cancer (CRC), and early detection is crucial for prevention. Traditional diagnostic methods invasive, prompting a need noninvasive biomarkers. This study aimed identify urinary metabolite biomarkers diagnosing CRPs construct nomogram based on screening. Patients Methods A total of 192 participants, including 64 CRP patients 128 healthy controls, were recruited. Urine samples analyzed using untargeted gas...

10.1002/cam4.70762 article EN cc-by Cancer Medicine 2025-04-01

Numerous studies have confirmed that intestinal flora is closely linked to the development of gastrointestinal polyps. However, precise causal link between them has yet be clarified. This study sought determine relationship gut microbiota and gastric, duodenal, colon, rectal polyps by Mendelian randomization (MR). We employed publicly available genome-wide association summary data conduct MR analysis. Gut were sourced from International MiBioGen Consortium, polyp obtained MRC-IEU Consortium....

10.5152/tjg.2025.24347 article EN cc-by The Turkish Journal of Gastroenterology 2025-05-02

Abstract Introduction: Cancer remains a leading cause of mortality worldwide. The multi-cancer early detection (MCED) test complements current screening methods improving and treatment outcomes. While most MCED tests focus on community populations, our MCTarg models were specifically designed to address both low-risk high-risk populations (e.g., those with conditions such as ulcerative colitis, adenomatous polyps, chronic bronchitis, tuberculosis, atrophic gastritis, H. pylori infection),...

10.1158/1538-7445.am2025-lb255 article EN Cancer Research 2025-04-25

Previous studies have demonstrated that microRNA (miRNA) are essential in tumor development and invasion. The close association between focal adhesion kinase (FAK) colon cancer (CC) has been previously reported. miRNA‑7 (miR‑7) inhibits the translation of FAK protein. Therefore, present study aimed to assess underlying molecular mechanism miR‑7 human CC cell lines, provide a novel therapeutic biomarker future. detected expression 60 tissues by reverse transcription‑quantitative polymerase...

10.3892/mmr.2015.4643 article EN cc-by Molecular Medicine Reports 2015-12-04

Abstract: Inflammatory bowel disease (IBD), which includes Crohn's and ulcerative colitis, is an intestinal with complicated pathological mechanisms. The incidence of IBD has been increasing in recent years, a significant negative impact on the lives patients. Therefore, it particularly important to find new therapeutic targets innovative drugs for development IBD. Recent studies have revealed that NLRP3 inflammatory vesicles can play role maintaining homeostasis sustaining immune response...

10.2174/0113894501255960231101105113 article EN Current Drug Targets 2023-10-01

Esophageal foreign bodies are often treated by endoscopy, but the treatment of esophageal perforation caused remains controversial. The purpose this study was to investigate safety and efficacy nonoperative bodies.We retrospectively analyzed 270 patients admitted our hospital for from January 2012 December 2020, all whom received treatment.The mean age 56 ± 17 years, fish bones were most common type body. A total 61.2% perforations in cervical esophagus. All initially, body removal rate...

10.14309/ctg.0000000000000451 article EN cc-by-nc-nd Clinical and Translational Gastroenterology 2022-01-01

Chronic colorectal inflammation has been associated with cancer (CRC); however, its exact molecular mechanisms remain unclear. The present study aimed to investigate the effect of Toll-like receptor 9 (TLR9) on development colitis-associated CRC (CAC) through regulation NF-κB signaling pathway. By using a CAC mouse model and immunohistochemistry, discovered that protein expression levels TLR9 were gradually upregulated during CRC. In addition, revealed be positively correlated Ki67 levels....

10.3892/ol.2020.11971 article EN Oncology Letters 2020-08-12

Circular RNA (circRNA) was first observed in the cytoplasm of eukaryotic cells 1979, but it not characterized detail until 2012, when high‑throughput sequencing technology more advanced and available. Consequently, mechanism circRNA formation its biological function have been progressively elucidated by researchers. is abundant exhibits a certain degree organization, timing disease‑specificity. Additionally, poorly degradable, meeting characteristics an ideal clinical biomarker. In present...

10.3892/ijo.2024.5637 article EN cc-by-nc-nd International Journal of Oncology 2024-03-15

The over-the-scope clip (OTSC) is an innovative device and has been successfully used in endoscopic treatment, however, there a lack of clinical data from China. aim this study to investigate the OTSC applications treatment upper non-variceal gastrointestinal bleeding (UNVGIB), perforations, fistulas In total, 80 patients were treated with one respectively as first-line therapy our endoscopy center between January 2016 November 2020. Among them, 41 had UNVGIB, 34 five fistulas. technical...

10.3389/fmed.2022.753956 article EN cc-by Frontiers in Medicine 2022-02-15

Colorectal cancer (CRC) has one of the highest incidences and mortality rates all malignancies worldwide. microRNAs (miRNAs) have been reported to be involved in many biological processes diseases. MiR-22-3p is considered progression, but its role CRC remains unclear. In this study, we detected that CRC, level miR-22-3p downregulated. antitumor effects CRC. can reduce proliferative, invasive migrative capacity cells. Luciferase reporter analyses confirmed KDM3A was a target miR-22-3p, which...

10.14670/hh-18-526 article EN PubMed 2022-12-01

As a comprehensive analysis of all metabolites in biological system, metabolomics is being widely applied various clinical/health areas for disease prediction, diagnosis, and prognosis. However, challenges remain dealing with the metabolomic complexity, massive data, metabolite identification, intra- inter-individual variation, reproducibility, which largely limit its widespread implementation. This study provided workflow clinical metabolomics, including sample collection preparation, mass...

10.3390/metabo12121168 article EN cc-by Metabolites 2022-11-24

Objective Inflammatory bowel disease (IBD) and alcohol use has become a significant growing public health concern. Alcohol been reported to be the most-avoided diet item among IBD patients. However, knowledge regarding impact of different classes alcoholic beverages on management is limited. Our study aims evaluate association frequencies, amounts, subtypes with risk. Methods The UK Biobank comprised 7,095 subjects 4,95,410 without IBD. Multivariate Logistic regression, stratifying analysis,...

10.3389/fnut.2022.918754 article EN cc-by Frontiers in Nutrition 2022-07-27

Abstract Background Colonoscopy is the standard and most effective screening tool for colonic diseases accuracy of colonoscopy depends on quality bowel preparation. The aim this study was to analyze risk factors inadequate preparation before colonoscopy. Methods In retrospective study, patients who underwent in 2018 received 3 L Polyethylene Glycol Electrolytes powder were included. They instructed drink 1.5 night 4–6 h procedure given doses 250 ml every 10 min with 30 simethicone Patient-...

10.1186/s12876-023-02796-2 article EN cc-by BMC Gastroenterology 2023-06-13

Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) been attracting attention as their application is expanding. Gastritis relatively rare a subtype of irAEs, particularly severe gastritis. Guidelines on its clinical management still remain undefined due limited data. Sintilimab inhibitor approved in China. Here we offer case sintilimab-induced...

10.2217/imt-2023-0325 article EN Immunotherapy 2024-03-26
Coming Soon ...